Medical Device | March 22, 2022
Thermo Fisher Scientific to showcase global innovation at DCAT Week 2022
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
The facility will produce 150 million vaccine doses per year
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
